Breast CancerLocalization01NCT05942105
Different Localization Techniques for Non-palpable Breast Lesions Comparison: a Retrospective and Multicentric Clinical Study
An observational study of Breast Cancer, run by Istituti Clinici Scientifici Maugeri SpA at 1 site in Italy.
Trial summary
Breast conservative surgery (BCS) is nowadays the standard of care for patients affected by early breast lesions. Screening programmes led to an increase of non-palpable breast lesion detection rates. Read more about this study
- Who is it for?
- Ages 18 to 85 years, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Breast conservative surgery
- Type of treatment
- Surgery or procedure
- How many people
- 1,064 participants
- Where
- 1 siteItaly
- Study dates
- 31 May 2023to 30 Sep 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- Women only
- Adult, Older adult
Study population: Breast cancer patients with non-palpable breast lesion candidated for conservative surgery
Who may be able to join
- Female sex;
- Patients who underwent breast conservative surgery for non-palpable occult breast lesions;
- Intraoperative localization of breast lesion with WGL, ROLL, magnetic seed, carbon dye;
- Preoperative diagnosis on histology or cytology of borderline lesion (B3 or C3) or malignant lesion (B4-B5 or C4-C5).
Who cannot join
- Diagnosis of benign breast lesion, both on preoperative needle breast biopsy (B2) or on fine needle breast aspiration (C2);
- Clinically palpable breast lesion;
- Localization of a non-palpable lesion through two or more different techniques;
- Breast tumor localization with clip in patients who underwent neoadjuvant chemotherapy.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Retrospective Multicentric Clinical Study Comparing Different Techniques for Intraoperative Localization of Non-palpable Breast Lesions During Breast Conservative Surgery
Breast conservative surgery (BCS) is nowadays the standard of care for patients affected by early breast lesions. Screening programmes led to an increase of non-palpable breast lesion detection rates. These patients are often eligible for BCS and an accurate preoperative localization technique for the detection of the lesion is required to guarantee a safe surgical excision. The primary goal of BCS is to obtain a complete resection of the tumor with disease-free surgical margins. The presence of tumor on surgical margins on postoperative histological examination of the specimen increases the risk of local recurrence and it requires a surgical re-excision. For all these reasons different techniques for localization of non-palpable breast lesions have been developed over time. Since '70s the wire guided localization (WGL) technique has represented the gold standard; however it has several limitations such as wire migration or fracture and patient referred discomfort related to wire placement. Over time, other techniques have been proposed, such as the radioguided occult lesion localization (ROLL), radioactive and magnetic seeds, carbon dye and ultrasound-guided preoperative localization.
Currently there are several studies of comparison between the WGL and the more modern techniques. All of these data claim the effectiveness of the new "wire-free" methodics ensuring a safe surgical resection with tumor-free margins and, in some cases, a better aesthetic result.
Read more
Studies of comparison between the modern techniques are limited. There is no scientific evidence of the superiority of a technique over the other. A multicentric Italian survey demonstrated that the most used localization techniques nowadays are the WGL, ROLL, the magnetic seed and the carbon dye.
The aim of this retrospective study is to compare these techniques to assess their efficacy in the localization of non-palpable breast lesions.
- Conditions
- Breast Cancer
- Being tested
- Breast conservative surgery
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Breast conservative surgeryProcedure or surgery
Breast conservative surgery after non-palpable lesion localization
| Study group | Role | What they receive |
|---|---|---|
| ROLL technique | Radioguided occult lesion localization Receives: Procedure: Breast conservative surgery | |
| MAGNETIC SEED | Magnetic seed localization Receives: Procedure: Breast conservative surgery | |
| WGL technique | Wire guided localization for non-palpable breast lesions Receives: Procedure: Breast conservative surgery | |
| CARBON | Carbon dye localization for non-palpable breast lesions Receives: Procedure: Breast conservative surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Free-surgical margins
Number of surgical procedures in which surgical margins are disease-free ("no ink on tumor" for invasive cancer and margin of 2 mm for in situ-carcinoma)
Measured: 6 months
Secondary outcomes (6)
Excess breast resection
Excess breast resection calculated by the "calculated resection ratio" (CRR=total resection volume/optimal resection volume)
Measured: 6 months
Surgery time
Surgery duration
Measured: 6 months
Hospitalization days
Number of hospitalization days
Measured: 6 months
Complications
Complications (after biopsy or surgery)
Measured: 6 months
Reintervention
Reintervention rates
Measured: 6 months
Follow up
5-years follow-up outcomes
Measured: 5 years after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jul 2023
- Study start31 May 2023
- Primary completion30 Mar 2025
- Study completion30 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,064 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fabio Corsi, Istituti Clinici Scientifici Maugeri SpA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05942105
- Sponsor's protocol ID
- 2776
- Acronym
- Localization01
- Status last verified
- May 2026
- First submitted
- 27 Jun 2023
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Retrospective Multicentric Clinical Study Comparing Different Techniques for Intraoperative Localization of Non-palpable Breast Lesions During Breast Conservative Surgery
- ClinicalTrials.gov ID
- NCT05942105
- Acronym / sponsor ID
- Localization01 / 2776
- Conditions
- Breast Cancer
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,064 participants (estimated)
- Lead sponsor
- Istituti Clinici Scientifici Maugeri SpAUniversity, hospital or other
- Study start
- 31 May 2023 (actual)
- Primary completion
- 30 Mar 2025 (actual)
- Study completion
- 30 Sep 2028 (estimated)
- First posted
- 12 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Breast conservative surgery (BCS) is nowadays the standard of care for patients affected by early breast lesions. Screening programmes led to an increase of non-palpable breast lesion detection rates. These patients are often eligible for BCS and an accurate preoperative localization technique for the detection of the lesion is required to guarantee a safe surgical excision. The primary goal of BCS is to obtain a complete resection of the tumor with disease-free surgical margins. The presence of tumor on surgical margins on postoperative histological examination of the specimen increases the risk of local recurrence and it requires a surgical re-excision. For all these reasons different techniques for localization of non-palpable breast lesions have been developed over time. Since '70s the wire guided localization (WGL) technique has represented the gold standard; however it has several limitations such as wire migration or fracture and patient referred discomfort related to wire placement. Over time, other techniques have been proposed, such as the radioguided occult lesion localization (ROLL), radioactive and magnetic seeds, carbon dye and ultrasound-guided preoperative localization.
Currently there are several studies of comparison between the WGL and the more modern techniques. All of these data claim the effectiveness of the new "wire-free" methodics ensuring a safe surgical resection with tumor-free margins and, in some cases, a better aesthetic result.
Studies of comparison between the modern techniques are limited. There is no scientific evidence of the superiority of a technique over the other. A multicentric Italian survey demonstrated that the most used localization techniques nowadays are the WGL, ROLL, the magnetic seed and the carbon dye.
The aim of this retrospective study is to compare these techniques to assess their efficacy in the localization of non-palpable breast lesions.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| ROLL technique | – | Procedure: Breast conservative surgeryRadioguided occult lesion localization |
| MAGNETIC SEED | – | Procedure: Breast conservative surgeryMagnetic seed localization |
| WGL technique | – | Procedure: Breast conservative surgeryWire guided localization for non-palpable breast lesions |
| CARBON | – | Procedure: Breast conservative surgeryCarbon dye localization for non-palpable breast lesions |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- Female only
- Age groups
- Adult, Older adult
- Study population
- Breast cancer patients with non-palpable breast lesion candidated for conservative surgery
Key inclusion criteria (4 listed)
- Female sex;
- Patients who underwent breast conservative surgery for non-palpable occult breast lesions;
- Intraoperative localization of breast lesion with WGL, ROLL, magnetic seed, carbon dye;
- Preoperative diagnosis on histology or cytology of borderline lesion (B3 or C3) or malignant lesion (B4-B5 or C4-C5).
Key exclusion criteria (4 listed)
- Diagnosis of benign breast lesion, both on preoperative needle breast biopsy (B2) or on fine needle breast aspiration (C2);
- Clinically palpable breast lesion;
- Localization of a non-palpable lesion through two or more different techniques;
- Breast tumor localization with clip in patients who underwent neoadjuvant chemotherapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Breast conservative surgeryBreast conservative surgery after non-palpable lesion localization | Procedure or surgery | CARBON, MAGNETIC SEED, ROLL technique, WGL technique |
Primary outcome
Free-surgical margins
Time frame: 6 months
Number of surgical procedures in which surgical margins are disease-free ("no ink on tumor" for invasive cancer and margin of 2 mm for in situ-carcinoma)
6 secondary outcomes
Excess breast resection
Time frame: 6 months
Surgery time
Time frame: 6 months
Hospitalization days
Time frame: 6 months
Complications
Time frame: 6 months
Reintervention
Time frame: 6 months
Follow up
Time frame: 5 years after enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
Related trials for Breast Cancer
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
RecruitingObservational study
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Cancer, Cancer Diagnosis
RecruitingPhase 3
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
Breast Cancer
RecruitingPhase 1/2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Liposarcoma, Prostate Cancer
RecruitingObservational study
Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer, run by Istituti Clinici Scientifici Maugeri SpA at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Free-surgical margins (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.